Saaid Safieddine
Paris, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications
Erratum: Efficacy and safety of SENS-501, a dual-AAV otoferlin gene therapy, for DFNB9 congenital deafness.
Journal: Molecular therapy. Advances
Published: August 07, 2026
Successful gene therapy for DFNB9 congenital deafness
Journal: Medecine sciences : M/S
Published: February 24, 2026
Efficacy and safety of SENS-501, a dual-AAV otoferlin gene therapy, for DFNB9 congenital deafness.
Journal: Molecular therapy. Advances
Published: December 04, 2025
Dual AAV gene therapy achieves recovery of hearing and auditory processing in a DFNB16 mouse model.
Journal: Clinical and translational medicine
Published: July 11, 2025
Adeno-associated virus-based rescue of Myo7a expression restores hair-cell function and improves hearing thresholds in a USH1B mouse strain.
Journal: The Journal of physiology
Published: June 18, 2025
MYO7A is required for the functional integrity of the mechanoelectrical transduction complex in hair cells of the adult cochlea.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: January 02, 2025
Cochlear gene therapy restores hearing and auditory processing in an atypical DFNB9 mouse model.
Journal: Communications medicine
Published: September 24, 2024
A free intravesicular C-terminal of otoferlin is essential for synaptic vesicle docking and fusion at auditory inner hair cell ribbon synapses.
Journal: Progress in neurobiology
Published: March 21, 2024
In utero adeno-associated virus (AAV)-mediated gene delivery targeting sensory and supporting cells in the embryonic mouse inner ear.
Journal: PloS one
Published: November 07, 2023
Recent advances and future challenges in gene therapy for hearing loss.
Journal: Royal Society open science
Published: May 12, 2023
Last Updated: 09/26/2026